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Summary
Background and Objective: Results of studies focusing on chronic kidney disease (CKD) among women with 
polycystic ovary syndrome (PCOS) are insufficient and controversial. This study aimed to evaluate the incidence rate 
of CKD in women with PCOS, compared to a control group of healthy women.
Methods: This study was a population-based cohort study conducted from among 1460 reproductive-age women 
including 156 women with PCOS and 1304 controls. Incidence rates per 1000 person-years of follow-up were 
calculated for PCOS and control groups. Cox proportional hazards regression with age as the time scale was used to 
estimate hazard ratios (HR) and 95% confidence intervals for developing CKD in relation to PCOS in both univariable 
and multivariable models.
Results: During a median follow-up of 12.9 years, 330 new cases of CKD were identified, including 25 PCOS women 
(14.8 per 1,000 person-years; 95% CI, 10-22) and 305 healthy controls (21.5 per 1,000 person-years; 95% CI, 19.2-
24.1). The results of the Cox model showed that the risk of CKD among women with PCOS and healthy women is 
comparable and women with PCOS did not have a higher risk of developing CKD compared to healthy women 
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potential confounders of smoking status, BMI, hypertension and diabetes at baseline and follow-up of study (multiple 
adjusted HR: 0.911; 95% CI: 0.600-1.383; P = 0.661).
Conclusion: Our population-based study with a long-term follow-up period showed that the risk of CKD in PCOS 
patients was similar to the general female population. Large studies, with long term follow-up and more diverse 
phenotypes are needed to confirm the findings.
Key words: chronic kidney disease, incidence, PCOS, population-based cohort study
1. INTRODUCTION
Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies among premenopausal women, with 
a prevalence of 5%-20% based on diagnostic criteria, reported by recent studies. 1, 2 Heterogeneous by nature, PCOS is 
characterized by the androgen excess in the absence of specific etiology, ovarian dysfunction with the main 
manifestations of menstrual irregularity and polycystic ovary morphology. 3, 4 The exact underlying etiology of the 
syndrome remains largely unclear, but emerging evidence suggests that multigenic abnormalities, epigenetic and 
environmental factors play a role in the pathophysiology of PCOS (5). It is well documented that PCOS is strongly 
associated with hyperandrogenemia, insulin resistance (IR) and compensatory hyperinsulinemia, 4, 6-8 as well as 
increased prevalence of traditional cardiovascular and metabolic risk factors particularly diabetes, obesity and central 
obesity, dyslipidemia, metabolic syndrome, and hypertension competed to age-matched women without PCOS. 9  
Chronic kidney disease (CKD) is a common disorder that refers to the long-term damage of renal function, eventually 
may progress into end-stage renal disease with a significantly increased rate of mortality. 10 It tends to be diagnosed in 
the presence of other cardiovascular and metabolic comorbidities including diabetes, hypertension and adiposity 
obesity that arises from many heterogeneous disorders which could irreversibly impair the renal function and 
structure, over months or years. 11, 12 In this respect, given the higher prevalence of cardio-metabolic risk factors in 
PCOS, an increased incidence of CKD in later life in these patients might be expected. However, the results of studies 
focusing on kidney dysfunction in PCOS are limited. Few studies have shown that some important markers for renal 
risk including pre/over microalbuminuria and decreased glomerular filtration rate (GFR) are more prevalent among 
women with PCOS. 13-16 In the in-vitro study, a higher risk of age-dependent chronic kidney injury was reported 
among the female PCOS rate. 17 However, the incidence of CKD in this population has not been addressed. Therefore, 
the aim of this study was to assess the incidence rate and risk of CKD among women with PCOS compared with 
healthy controls in a long-term population-based study. 
2. METHODS
This study was approved by the ethics committee of the Research Institute for Endocrine Sciences and written 
informed consent was signed by all participants, after an explanation of the purpose of the study to them. 
This study was a population-based cohort study conducted from among reproductive aged women who participate 
from Tehran Lipid and Glucose Study (TLGS). In brief, the TLGS is an ongoing long-term community-based 
longitudinal study conducted on a representative sample of Tehran, the capital of Iran. TLGS was initiated from 1998, 
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mainly cardiovascular diseases including diabetes, heart attacks, and stroke, cancers, chronic respiratory and kidney 
diseases. A total of 15005 people aged ≥ 3 years were recruited. Data on different risk factors for noncommunicable 
diseases, demographic variables, and reproductive and obstetrics characteristics were collected during face-to-face 
interviews conducted every 3 years by trained staff. Every follow-up visit included a comprehensive questionnaire, 
information on general anthropometrics, a physical examination, and blood samples collection. Detailed descriptions 
of the TLGS have been published elsewhere. 18 
2.1. Study Population
For the present study, all reproductive-aged women who participate in the first phase of the TLGS (1998–2001) and 
attended at least one follow-up visit until March 31, 2017, were recruited. Women who were pregnant, were surgical 
/natural menopause, had undergone the hysterectomy or oophorectomy, who had a history of endocrine disorders 
including Cushing's syndrome, congenital adrenal hyperplasia or androgen secreting neoplasm, hyperprolactinemia, 
thyroid disease or any corticosteroid and nephroprotectant medication including metformin usage (n = 138). We also 
excluded women if they had isolated menstrual irregularity or hyperandrogenism (n = 244). The remaining 
participants (n = 1702) fulfilled the eligibility criteria for the study and were classified as follows: women with PCOS 
(n = 178) and healthy eumenorrheic, non-hirsute control women (n = 1524). For detecting the new cases of CKD 
among these populations, women who suffered from CKD at the baseline (n = 81) and had missing data on CKD (n = 
30), were lost to follow up (n = 131) were excluded from the final analysis. Analyses were conducted on a total of 
1460 women (156 PCOS and 1304 healthy controls) to identify the incidence and risk of CKD incidence over a 
median of 12.9 years of follow-up (Figure 1).
2.2. Measurements 
Data about the PCOS in TLGS female population were specifically collected at the first phase of TLGS (1998-2001) 
and were updated at 4th, 5th, sixth and 7th follow-up visits. A comprehensive questionnaire on reproductive lifespan 
including menarche, menopause, menstrual regularity, parity, abortion, type and duration of contraception usage, 
infertility, and lactation were collected through face to face interviews by trained staff. Androgen excess 
manifestations were evaluated using valid tools. The hirsutism scores were evaluated using the modified Ferriman-
Gallwey (mFG) scoring scale. Acne was assessed based on its type, number, and distribution. For hormonal 
assessments, fasting venous blood sampling were collected on the third day of spontaneous or progesterone 
withdrawal menstrual period. Another serum was obtained on any one day between days 22-24 of the cycle for the 
measurement of progesterone (P4) to confirm ovulatory function (P4 level < 4 ng/ml, indicating anovulation) among 
those with the predictable and regular menstrual cycle. This data was specifically collected. In addition, the general 
anthropometric and physical examinations including hirsutism using the modified Ferriman-Gallwey scoring method, 
19 has been performed by a general practitioner. Body weight was measured with the least clothes using a digital scale 
and rounded to the nearest 100 grams. Likewise, height was measured without shoes in the standing position and 
normal posture of shoulders with a tape measure. Body mass index (BMI) was calculated using the formula [weight in 
kilograms (kg) divided by height squared (m2)]. Waist circumference (WC) was measured with an unstretched tape 
measure at the level of the umbilicus, without any pressure to the body surface. Hip circumference (HC) was 
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systolic blood pressure (SBP) and diastolic blood pressure (DBP) twice on the right arm in a seated position using a 
standard mercury sphygmomanometer after 15 mines of rest and the mean of these measurements was recorded. A 
baseline overnight fasting venous blood sample was obtained on the second or third day of the participant’s' 
spontaneous or progesterone-induced menstrual cycles, and overnight fasting blood samples were obtained at every 
follow-up visit for biochemical assessments. All blood analyses were performed at the TLGS research laboratory on 
the day of blood collection. Triglyceride (TG) levels were assayed using glycerol phosphate. Total cholesterol (TC) 
was assayed using the enzymatic colorimetric method with cholesterol esterase and cholesterol oxidase. The level of 
high-density lipoprotein cholesterol (HDL-C) was measured after precipitation of the apolipoprotein B (apo B)-
containing lipoproteins with phosphotungstic acid. We used a modified Friedewald to calculate LDL-C. All metabolic 
analyses were performed using related kits (Pars Azmon Inc., Tehran, Iran) and a Selecta 2 autoanalyzer (Vital 
Scientific, Spankeren, Netherlands). Intra-assay and inter-assay coefficients of variations for TG, TC, HDL-C, and 
LDL-C were less than 2.1, 1.9, 3, and 3%, respectively. Dehydroepiandrosterone sulfate (DHEAS), total testosterone 
(TT), and androstenedione were measured by enzyme immunoassay (Diagnostic Biochem Canada). Sex hormone 
binding globulin was measured by immunoenzymometric assay (Mercodia). All enzyme-linked immunosorbent assay 
(ELISA) tests were performed using the Sunrise ELISA Reader (Tecan). The free androgen index was calculated 
using the following formula: TT (nmol/L) _ 100/sex hormone binding globulin (nmol/L). The intra-assay and 
interassay coefficients of variation for TT were 3.6% and 6.0%, for DHEAS 1.9% and 3.2%, for sex hormone-binding 
globulin 1.1% and 4.1%, and for androstenedione 2.2% and 3.5%. Serum creatinine (cr) levels were assayed by 
kinetic colorimetric Jaffe. The sensitivity of the assay was 0.2 mg/dL (range, 18–1330 µmol/L (0.2–15 mg/dL). 
Reference intervals based on the manufacturer’s recommendation was 53–97 µmol/L (0.6–1.1 mg/dL) in men. Intra-
assay and inter-assay CVs were less than 3.1% in both baseline and follow-up phases. All biochemical assays were 
performed using commercial kits (Pars Azmoon Inc., Tehran, Iran) by a Selectra 2 autoanalyzer (Vital Scientific, 
Spankeren, The Netherlands). Assay performance was monitored after every 25 tests using lyophilized serum controls 
in normal and pathologic ranges and all samples were analyzed when the internal quality control met the standard and 
acceptable criteria. 20
2.3.Terms definitions
Since the study was begun in 1998, the diagnosis of PCOS was based on the U.S. National Institutes of Health (NIH) 
criteria, including chronic oligo/anovulation, and either biochemical or clinical hyperandrogenism after exclusion of 
other known related disorders. 21 Oligo/anovulation was defined as either regular or irregular menstruation ≥ 34 days 
or a history of eight or fewer menstrual cycles in a year. The clinical symptoms of hyperandrogenism included 
hirsutism diagnosed based on a standardized scoring system of modified Ferriman-Gallwey scale ≥8, acne, or 
androgenic alopecia. Biochemical hyperandrogenism was assessed as an increased level of one or more serum 
androgens—including dehydroepiandrosterone sulfate, testosterone, or androstenedione— above the 95th percentile, 
determined in the selected healthy non-hirsute eumenorrheic women in the study population. 22 
According to American Diabetes Association criteria, diabetes was defined as fasting plasma glucose ≥ 126 mg/dL, or 
2-hour plasma glucose ≥ 200 mg/dL, or using medications for a previous diagnosis of DM (23). Hypertension was 
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and Treatment of High Blood Pressure as a mean systolic blood pressure ≥ 140 mm Hg, mean diastolic blood pressure 
≥ 90mmHg, or undergoing treatment for hypertension. 24
According to the Kidney Disease Outcome Quality Initiative guidelines (K/DOQI), chronic kidney disease is defined 
as Glomerular Filtration Rate (GFR) <60 mL/min/1.73 m2 for >3 months (25). In this study, GFR was estimated using 
the abbreviated prediction equation, provided by the Modification of Diet in Renal Disease (MDRD) study as follows: 
GFR = 186 × (scr 2  - 1.154) × (age2  - .203) × 0.742. In this equation, estimated GFR (eGFR) is expressed as mL/min 
per 1.73 m2 and serum creatinine (Scr) is expressed as mg/dL. According to guidelines, CKD is considered as eGFR 
below than 60 mL/min/1.73 m2 occurring at any time during the follow-up period. 25, 26 
2.4. Statistical Analysis
Baseline characteristics of study participants in two groups were compared using independent t-tests, and Mann-
Whitney test based on the normal distribution of continuous variables and the chi-square test for categorical variables.. 
The event date for the incident of CKD was defined as the midpoint between the date of the follow-up visit at which 
the CKD was diagnosed for the first time and the most recent follow-up visit before the diagnosis. The follow-up time 
was drawn from the difference between the calculated midpoint date and the date of entry into the study for each 
participant. For censored participants, the time was calculated as the interval between the first and the last observation 
dates. The incidence rate of CKD was calculated per 1000 person-years among the PCOS and control groups.. The 
cumulative incidence of CKD which was estimated using the Kaplan-Meier method and was compared among women 
with PCOS and the healthy women using the log-rank statistic are shown in Figure 2. Univariate and multiple Cox 
proportional hazards regression models were used to estimate the hazard ratio (HR) of CKD in relation to PCOS. In 
this model, age was considered as the time scale and as well as the baseline hazard assumes that each woman's 
observed risk period was started at birth and was not adjusted for age truncation. The proportional hazards assumption 
of the model was assessed via the Schoenfeld residual test (p=0.725 and p=0.738 respectively for Univariate and 
multiple models) and rechecked graphically by log (-log) survival curves that were appropriated. BMI, hypertension 
(HTN), type 2 diabetes (T2DM) and current smoking status at both baseline and during the follow-up of study and 
also anti DM (including metformin) and anti HTN medications usage during the follow-up of study were evaluated as 
confounding covariates. All statistical tests were two-tailed, and P < 0.05 was considered statistically significant. The 
Statistical Package for Social Sciences (SPSS version 16; SPSS Inc.) and STATA software (version 12; STATA Inc.) 
were used for data analysis.
3. RESULTS
In total, 156 patients with PCOS and 1304 healthy women were observed for a median (IQR) follow-up time of 12.9 
(10.8-14.0) years. The characteristics of the study participants are presented in Table 1. The women with PCOS were 
significantly younger than the healthy controls (26.4 ± 8.5 vs. 28.7 ± 8.6 years, respectively; P = 0.002). The mean 
BMI and WC in the PCOS patients and healthy women were similar (26 ± 5.2 vs. 25.3 ± 4.7, P = 0.085) and (82.7 ± 
12.5 vs. 81.3 ± 11.6, P = 0.172), respectively. However, the exception for androgens levels there were not any 
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Among the 1460 women who were free of CKD at baseline, 25 PCOS cases (14.8 per 1000 person-years; 95% CI, 10-
22) and 305 healthy women (21.5 per 1000 person-years; 95% CI, 19.2-24.1developed CKD over 15833 person-year 
of follow up. The results of Cox model showed that the risk of  CKD among women with PCOS and healthy women 
are comparable and women with PCOS did not have a higher risk of developing CKD compared to healthy women 
(unadjusted HR: 0.886; 95% CI: 0.883-1.328–3.9; P = 0.551). The results remained unchanged after adjustment for 
potential confounders of smoking status, BMI, hypertension and diabetes at baseline and follow-up of study (multiple 
adjusted HR: 0.911; 95% CI: 0.600-1.383; P = 0.661). 
4. DISCUSSION
This study was a long-term, prospective, population-based study that presents new findings describing the incidence 
rate and risk of CKD between women with PCOS and healthy controls. The results of the present study suggest that 
the risk of developing CKD among women with PCOS is comparable with the general female population after 
adjustment for potential related confounders. 
PCOS and CKD are important and common noncommunicable disorders globally (12, 27). CKD, a state of 
progressive loss of kidney function, mostly relates to underlying cardio-metabolic disturbances. However, there are 
some literature showed that women with PCOS may have a higher prevalence of cardio-metabolic risk factors mainly 
due to hyperandrogenism, insulin resistance, 4, 28, 29 obesity and central obesity which may lead to disturbances of 
growth factors, adipokine hormones, and pro-inflammatory factors 30, 31 and also higher serum level of endothelin-1 
and subsequently potential endothelial dysfunction. 32 This evidence led to the theory that PCOS patients may have 
higher cardio-metabolic related events, including CKD in later life. 
However, much less is known regarding the underlying mechanism of kidney function in PCOS. There is some 
evidence showed that hyperandrogenism as one of the main criteria of PCOS is correlated with kidney dysfunction, 
particularly in tubular epithelial cell injury. In this respect, it is showed that higher testosterone levels could activate 
the apoptotic pathway in human renal tubule cells which stimulates apoptosis and inflammation in kidney tubulogenic 
cells and further tubular proteinuria and chronic renal diseases. 16, 33 In addition, although all PCOS patients did not 
suffer from IR, 34 but its high prevalence and compensatory hyperinsulinemia may be associated with impaired long-
term renal function in PCOS. Hyperinsulinemia may stimulate mesangial hyperplasia, increases low-grade 
inflammation, glomerular filtration and vascular permeability which may lead to urinary albumin extraction (UAE). 13, 
35 However, the role of insulin is still not fully understood and in some studies, an association between UAE and 
insulin was not observed. 36
Limited efforts have been made to investigate PCOS-related kidney dysfunction. Some studies have reported some 
evidence including the higher prevalence of pre-microalbuminuria 15, 37, 38 and microalbuminuria (13, 39), increased 
level of cystatin C 40 and urinary albumin excretion, 13 higher rate of glomerular filtration rate 14, 41 as well as 
hyperuricemia 14, 41, 42 which may be associated with kidney dysfunction among women with PCOS. Likewise, Duleba 
et al. (2010) in the observational study of 63 normotensive and non-diabetic PCOS patients evaluated the overt 
microalbuminuria and urinary albumin excretion (UAE) as a key indicator of renal function and endothelial 
dysfunction. However, overt microalbuminuria was detected in a significant proportion of subjects with PCOS, and 
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PCOS animal models showed that chronic and persistent hyperandrogenism in PCOS significantly increased the risk 
for the development of chronic kidney disease with advanced age. 13 In a recently published study, Song et al. (2019) 
performed a prospective survey to establish a link of PCOS with kidney injury. In this study, 55 PCOS patients and 69 
healthy controls were selected from reproduction medicine hospital and correlation analyses between serum 
testosterone and some renal functional manifestations were assessed. The results of the study showed that urinary 
albumin to creatinine ratio (UACR), as a glomerular injury indicator among PCOS patients was significantly higher 
than non-PCOS controls, suggesting that PCOS is closely associated with kidney injury. Further, the serum 
testosterone level in PCOS had a positive association with the urinary protein excretion levels than potentially shows 
the injury in renal tubules. They concluded that PCOS associated with kidney injuries and serum testosterone plays a 
critical role in PCOS-associated kidney injury. 16 
However, our present population-based study found no increase in the incidence of CKD in women with PCOS 
compared with the non-PCOS controls and did not confirm those reports. The probable reason for this discrepancy 
was that all those studies reported these associations have been limited by several biases. The clinical-based setting of 
studies that may include severe phenotype of PCOS patients, un-adjustment for potential confounders such as age or 
BMI that strongly associated with renal function, the cross-sectional design of studies and lack of comparison with 
healthy control group means that those findings should be interpreted with cautious. 
Notably, since hyperandrogenism and IR as critical factors in PCOS-associated kidney injury, 16 are correlated with a 
spectrum of clinical, biochemical and cardio-metabolic severity of PCOS 5, 34 this may suggest that severe form PCOS 
are associated with CKD. Likewise, Although the available evidence supporting this assumption is insufficient, 
however, community-based setting studies with including milder phenotypes of PCOS who might have never been 
referred to a clinic, reported that PCOS is not associated with worsening of cardio-metabolic health later in life. 43-46 
However, results from these studies cannot be directly compared with our results since these studies did not 
investigate the risk of CKD in PCOS. But these studies suggest that representative of PCOS population sampling is 
strongly associated with the cardio-metabolic associated events findings.  
One potential hypothesis is that there is evidence demonstrating that women with PCOS are more likely to have their 
lifestyle modification with various interventions, including diet, exercise or medication. 47-49 Given the better lifestyle 
of PCOS women, similar risk of CKD in women with PCOS compared to healthy women in later life might be 
explained.  However, since we did not evidence to support this hypothesis, further studies are warranted to explore it. 
Moreover, it is worth noting that estrogen has nephroprotective effects due to attenuating the glomerulosclerosis and 
tubulo-interstitial fibrosis. 50 However, since women with PCOS have extended exposure to endogenous estrogen due 
to later age at menopause and lower conception rate, 51 this could be a benefit for kidney function among PCOS 
patients. 
However, Since we used NIH criteria for PCOS diagnosis, the prevalence of PCOS in this study was relatively lower 
than studies that used Rotterdam or Androgen Excess Society (AES) for PCOS definition. 52 In addition, The mean 
BMI at baseline among women with PCOS and healthy women showed no statistically significant difference in our 
study and were much less than observed in Western countries. The population-based nature of our study, which 
included less severe phenotypes that might have never been referred to a clinic, may explain these findings. 53 In 
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This study has some strengths and limitations. The longitudinal nature of the data with a long-term follow-up period 
helped us to present the valuable estimation of the CKD risk among women with PCOS. Moreover, the population-
based setting of the study let us have a representative sample of the PCOS population due to reducing selection bias. 
Therefore the findings may not be comparable with those studies with clinical-based studies. In addition, adjustment 
of the related potential confounders produced valuable results. However, lifestyle modifications that would give more 
precise information for tracking of CKD in PCOS were not assessed in this study. Moreover, our results are limited to 
a specific urban population in one geographical area among population who willing to participate in a study and 
therefore it cannot be generalized to all other geographical and ethnicity population. Moreover, since the study was 
begun in 1998, the diagnosis of PCOS was based on the U.S. National Institutes of Health (NIH) criteria, including 
chronic oligo/anovulation, and either biochemical or clinical hyperandrogenism after exclusion of other known related 
disorders. Hence, all PCOS women in our study had both hyperandrogenism and oligo/anovulation; as a result 
subgroup analysis according to the PCOS phenotypes was not possible. 
In conclusion, our population-based study with a long-term follow-up period showed that the incidence and risk of 
CKD were similar to the general female population, may suggest an individualized approach for the monitoring of the 
development and progression of CKD in women with PCOS. However, large studies, with long term follow up and 
more diverse phenotypes are needed to confirm the findings.
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Table 1. Baseline characteristics of PCOS and healthy control groups. 
 
Characteristic PCOS  Healthy control Unadjusted  
 n=156 n=1304 P-value 
Age (y) 26.4 (8.5) 28.7 (8.6) 0.002 
BMI (kg/m2) 26 (5.2) 25.3 (4.7) 0.085 
WC (cm) 82.7 (12.5) 81.3 (11.6) 0.172 
WHR 0.8 0.8  0.543 
SBP (mm Hg) 107.6 (11.6) 108.5 (11.8) 0.380 
DBP (mm Hg) 73.1 (9.1) 72.8 (9.1) 0.659 
TC (mg/dL) 189.2 (44.3) 185.8 (39.9) 0.317 
TG (mg/dL) * 106 (80.2-160) 99 (73-147) 0.058 
HDL-C (mg/dL) 44.4 (11.4) 44.5 (10.6) 0.934 
LDL-C (mg/dL) 118.6 (36.5) 117.5 (34.4) 0.694 
FBS (mg/dL) 87.1 (9.1) 88.1 (17.6) 0.518 
Bs-2hPG (mg/dL) 108 (32) 105.5 (34.7) 0.492 
Total T (ng/mL)  0.5 (0.3–0.7)  0.4 (0.2–0.6) 0.001 
SHBG (nmol/L)  37.0 (27.0–43.0)  45.5 (39.0–54.8) 0.001 
FAI  3.1 (2.2–3.8)  2.3 (1.5–4.2) 0.001 
DHEAS (mg/dl)  120.0 (77.0–162.3)  125.2 (75.5–145.3) 0.001 
A4 (ng/mL)  1.4 (0.6–2.3)  0.8 (0.5–1.7) 0.001 
Modified FG score  10.0 (9–12)  1 (0–4) 0.001 
Medical history     
 Diabetes, n (%) 2 (1.2) 30 (2.3) 0.569 
 Hypertension, n (%) 10 (6.5) 58 (4.4) 0.309 
Current smoking status, n (%) 2 (1.2) 23 (1.7) 0.543 
Note: Data were presented as mean (standard deviation)  or median(IQR) or number(%) as were appropriated. 
BMI = body mass index; BS-2hPG = 2-hour postprandial blood sugar; DBP = diastolic blood pressure; FBS = 
fasting blood sugar; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein 
cholesterol; SBP = systolic blood pressure; TC = total cholesterol; TG = triglyceride; WC = waist 
circumference; WHR = waist-to-hip ratio;  
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